Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Canary Networks Investor Presentation (August 2015)
16 slides from Proteomics International Laboratories's conference presentation, Aug 19, 2015
Slide 1: Investor Presentation | Canary Networks
Proteomics International Laboratories Ltd For personal use only Investor Presentation | Canary Networks Melbourne & Sydney | 19 & 20th August 2015 Global leader & innovator in the field of proteomics ASX: PIQ 1 Proteomics International Laboratories Ltd
Slide 2: Disclaimer & forward-looking statements
Disclaimer & forward-looking statements For personal use only This Presentation is provided by Proteomics International Laboratories Ltd (PILL, the Company). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in
Slide 3: Changing lives......
Changing lives...... For personal use only DNA shapes our lives. The Human Genome Project, to map human DNA, was the single largest undertaking in the history of biological science. Completed in 2003 it was a US$4 billion international collaboration. Today, cumulative benefits are estimated at US$1
Slide 4: Corporate overview
Corporate overview For personal use only Capital Structure Shareholders ASX code PIQ Top 20 Shareholders 69.3% Shares on issue 50.6m Major Shareholders Listed (@ 20c) 16th April 2015 Richard Lipscombe 31.9% XYLO Pty Ltd 12.4% Market capitalisation (@ 34c) $17.2m John Dunlop 7.5% 4 month price range
Slide 5: Board & management
Board & management For personal use only Terry Sweet FAICD, Chairman Director of several listed companies over the past 30 years in both executive and non-executive capacities. Companies include XRF Scientific Ltd, where he was Managing Director for 4 years, Western Biotechnology Ltd, Heartlink
Slide 6: Introducing PILL
Introducing PILL For personal use only Established, revenue generating Company – Established 2001 Global leader & innovator in field of proteomics World’s first company to receive ISO 17025 laboratory accreditation for proteomics services Proven technology with established IP Operates from purpose b
Slide 7: Engaged in high growth markets
Engaged in high growth markets For personal use only Diagnostics (biomarkers) market is $24.1bn 1 Predicted to reach $45.6bn by 2020 1. ‘Omics’ technology holds ~75% share. Proteomics market to be $20.8bn by 2018 2 Bio-engineered protein drugs was $152bn (2013) CAGR 7.2%. 7 of world's top 10 selling
Slide 8: Business model
Business model For personal use only Three synergistic business units Unifying platform technology - leverage & efficiency Existing revenue generation & deal flow - multiple major upside opportunities 8 Proteomics International Laboratories Ltd
Slide 9: Proprietary platform technology
Proprietary platform technology For personal use only One proven and proprietary platform, multiple uses: Biomarker discovery, biosimilars testing (analytics), drug discovery The methodology was developed as part of a $7m self-funded R&D program 9 Proteomics International Laboratories Ltd
Slide 10: Diagnostics – personalised testing
For personal use only Diagnostics – personalised testing Unlike our genes, the protein make-up in our bodies changes considerably over time – e.g. a cancerous cell will have significantly different proteins to a healthy cell. PIQ's proteomics-based technology platform is developing next generation d
Slide 11: Predictive test for diagnosis of diabetic kidney disease
Predictive test for diagnosis of diabetic kidney disease For personal use only International Diabetes Foundation estimates 382 million people globally have diabetes - expected to rise to 1 in 10 of world population by 2035; in Australia alone, total cost to the health system and productivity loss is
Slide 12: Analytical services
For personal use only Analytical services PIQ offers one of the world’s only internationally accredited laboratories for proteomics analysis. This analytical services business leverages its proteomics technology platform’s ability to test & validate the protein composition of a wide range of product
Slide 13: Analytical services
Analytical services For personal use only Proven track record in analysing protein drugs Blue chip, global client base with 50% export income (priced in USD) Analytical & consulting services income in 2015 grew ~20% year on year Major contracts post listing: a2 Milk Company (quality control testing)
Slide 14: Transactions in our sector
Transactions in our sector For personal use only Proteome Sciences (AIM: PRM) Biomarker discovery, validation and assay development in Alzheimer's, breast cancer & cosmetics. Revenue GBP1.56m in 2014; raised A$5m June 2015; market cap A$80m (14th Aug 15). Applied Proteomics Inc, private San Diego-ba
Slide 15: Why PIQ?
Why PIQ? For personal use only Leveraged business model Established income ~$1m per annum Analytics division underpins cash flow and reduces burn Strong IP position Patents granted for methodology Patents pending in major jurisdictions for ground-breaking PromarkerD diagnostic Proven technology plat
Slide 16: Please contact
Please contact For personal use only Richard Lipscombe Managing Director, Proteomics International M: +61 414 405 631 E: r.lipscombe@proteomicsinternational.com T: +61 8 9389 1992 www.proteomicsinternational.com Chuck Morrison Head of Business Development M: +1 617 331 2975 E: c.morrison@proteomicsi
Proteomics International Laboratories — Canary Networks Investor Presentation (August 2015) on 6ix